INMB INmune Bio Inc

$INMB & $QUBT collaboration is a very important project. If any progress is made on the Alzheimer's study, I believe there'll be a moonshot within minutes of the PR. Get to work!

$INMB INmune Bio Establishes Global Commercialization Framework for Ebstrocel Through Strategic Agreement with Uniphar We are pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization,” said Ruth Rostron, Head of Expanded Access at Uniphar. “Uniphar has built an integrated global platform to help innovative medicines navigate the complexities of international access, distribution and commercialization. We believe our infrastructure and experience are well suited to support INmune Bio’s strategy for Ebstrocel, beginning with named-patient access opportunities and expanding as the product progresses through its regulatory and commercial journey.”

$INMB Yes, Martin Shkreli shorted INmune Bio (INMB). Regulators have formally alleged that Shkreli built a short position in INmune Bio during his recent livestreamed trading challenges. Shkreli has publicly targeted the company on social media and his livestreams, laying out an extensive short thesis against INMB's lead Alzheimer's drug candidate, XPro1595. He predicted a 90% crash in the stock price, arguing that the clinical data was weak and that the drug's mechanism (TNF-alpha inhibition) would fail in clinical trials. This specific short position has also caused him legal trouble. In October 2026, the Federal Trade Commission (FTC) and several states filed a motion to hold Shkreli in contempt of court. Regulators argue that his short positions in biotech companies like INMB, Cassava Sciences, and Capricor Therapeutics violate his existing lifetime ban from participating directly or indirectly in the pharmaceutical industry.

$INMB great news INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027 Final pre-MAA package submitted to MHRA on October 20, 2026 Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks U.S. BLA expected to be submitted in Q2, 2027

$INMB submitted its final pre-MAA package to the UK regulator for Ebstrocel, targeting mid-2027 approval.

$INMB RARE just sold their voucher for 210M, we will be getting a voucher (upon approval) for 4x the companys current value

$INMB Management is bad, stuck here for 2 years, cut my losses, there are other ways to still make something in 2 years 😂. Now no money again, another postponement. Coincidentally 02/27 just when the cash runs out. What are they going to come up with next to fleece people? Good luck to the believers and I hope at least $7 for you! Cheers

$INMB INMB — Key catalysts to look forward to 🧬🚀 💰 Fresh capital raised: $4.5M offering potentially reduces near-term financing pressure and helps fund operations. 🇬🇧 Ebstrocel: Targeting UK marketing application submission in early February 2027. 🇺🇸 U.S. BLA: Ebstrocel submission targeted for Q2 2027. 🧠 XPro1595: FDA-aligned Phase 2b/3 development strategy for Alzheimer's. 🔬 Myelin biomarker data: Encouraging statistically significant findings supporting further investigation. 🌍 Commercial potential: Uniphar agreement provides a framework for international named-patient access.

$INMB You would think there would be a pump knowing that someone bought 4.5 million of shares at a 1.65 price..

$INMB there were 3 million shares that can be purchased at $1.50 per share over the next six months. That’s the max this price will go to now pending any major news. The CEO screwed investors as usual.

$INMB 1.65 is going to be interesting because thats where the sale is taking place for the shares via the dark pool.

$INMB it's been straight down since August and now a round of dilution at the bottom. Do you ever get the feeling that management is not aligned with the shareholders?